| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 93.74 | 5.9% | 19.2% |
| Total Income | 94.85 | 8.1% | 19.0% |
| Expenditure | 96.34 | 13.7% | 15.9% |
| PBT | -1.49 | 82.2% | 158.8% |
| Net Profit | -3.56 | 56.3% | 309.6% |
| OPM | 9.10% | 9.63pp | 2.77pp |
| NPM | -3.76% | 4.14pp | 3.02pp |
| EPS | 5.17 | 56.3% | 307.1% |
Pharma manufacturer posted a widened net loss (-3.56cr vs -0.87cr YoY) on a 19% revenue decline with both OPM and NPM compressing YoY, a clear deterioration rather than a turnaround.
Bharat Parenterals Subsidiary Expands Facility to ₹300 Cr for Biologics
11 Aug 2026 · 11 Aug, 3:40 pm
Summary
Bharat Parenterals Limited announced a strategic enhancement to its wholly owned subsidiary, Varenyam Biolifesciences Private Limited's, upcoming Savli manufacturing facility. The facility will be upgraded to include biologics and biosimilar CDMO capabilities, in addition to its existing oncology focus, targeting markets such as the United States and European Union. The Phase 1 capital expenditure has been revised to ₹300 crore from ₹150 crore, with an expected completion date of Q2 2028. Management believes this expansion will capitalize on gaps in the global biologics supply chain and present a larger, more stable revenue opportunity.
Key Highlights
- 1
Varenyam Biolifesciences Private Limited, a wholly owned subsidiary of Bharat Parenterals Limited, is upgrading its upcoming Savli manufacturing facility.
- 2
The facility upgrade will enable it to offer biologics and biosimilar CDMO services, in addition to its existing oncology-focused capability.
- 3
The Phase 1 capital expenditure for the Savli facility has been revised to ₹300 crore, an increase from the previously envisaged ₹150 crore.
- 4
The upgraded facility aims to cater to the United States, European Union, and SRA Rest-of-World markets.
- 5
The target completion date for the upgraded facility is Q2 2028, subject to regulatory and commissioning timelines.
- 6
Management views this expansion as a structurally larger and stickier revenue opportunity in the evolving biologics and biosimilar CDMO market.
Management Comments
Unknown
The Company believes the expanded scope will strengthen the long-term capabilities of the facility and enable it to participate in the evolving biologics and biosimilar CDMO opportunity, while retaining its existing oncology focus.
Unknown
Management views this as a structurally larger and stickier revenue opportunity than the Company's previous Regulated RoW- facing model, given the multi-year, relationship-driven nature of CDMO engagements and the higher barriers to entry in biologics manufacturing.
Informational and educational content only. Not investment advice.